Back to results
US 2012/0252767 A1Published application
Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
AssigneeTeva Women's Health, Inc.
InventorsCharles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
Life of this patent
Estimating the term…
Abstract
The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
Claims31
-135. (canceled)
A method of contraception, the method comprising:
- administering to a female in need thereof a dosage comprising estrogen and progestin for a period of 83 to 89 consecutive days,
- wherein the dosage comprising estrogen and progestin is administered in at least three phases,
- wherein the daily dosage of estrogen in the first phase is equivalent to 15 μg to 25 μg of ethinyl estradiol, the daily dosage of estrogen in the second phase is equivalent to 20 μg to 30 μg of ethinyl estradiol, and the daily dosage of estrogen in the third phase is equivalent to 25 μg to 35 μg of ethinyl estradiol,
- wherein the total daily dosage of estrogen and progestin in the second phase is higher than the total daily dosage of estrogen and progestin in the first phase, and
- wherein the total daily dosage of estrogen and progestin in the third phase is higher than the total daily dosage of estrogen and progestin in the second phase.
2 more elements
A method of contraception, the method comprising:
- administering to a female in need thereof a dosage comprising estrogen and progestin for a period of greater than 30 consecutive days,
- wherein the dosage comprising estrogen and progestin is administered in at least two phases,
- wherein the daily dosage of estrogen in the first phase is equivalent to 15 μg to 25 μg of ethinyl estradiol,
- the daily dosage of estrogen in the second phase is equivalent to 20 μg to 30 μg of ethinyl estradiol,
- wherein the total daily dosage of estrogen and, progestin in a second phase is higher than the total daily dosage of estrogen and progestin in the first phase, and
- wherein the daily dosage of progestin in the second phase is less than twice the daily dosage of progestin in the first phase.
3 more elements
Dependencies are inferred from the claim text.